Lotilaner Formulations for Systemic Tick Eradication in Humans
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for improved systems and methods to treat and prevent vector-borne diseases, particularly malaria and other pathogenic conditions, as existing treatments are inadequate.
Innovation Solution
The use of isoxazoline parasiticide formulations, including fluralaner, lotilaner, and afoxolaner, administered orally, parenterally, or transdermally, to inhibit the health or life cycle of Plasmodium species and other vector-borne organisms through systemic bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments for vector-borne diseases are used, then treatment can be provided, but the treatments are inadequate and ineffective
Solution Approach 1:
The patent changes the chemical parameter by introducing isoxazoline compounds (fluralaner, lotilaner, afoxolaner) with specific molecular structures that have proven efficacy against vector-borne pathogens. These compounds represent a parameter change from existing inadequate treatments to new chemical entities with improved therapeutic properties
Solution Approach 2:
The patent employs composite pharmaceutical formulations containing isoxazoline compounds combined with other therapeutic agents. These composite treatments integrate multiple active ingredients to address the inadequacy of single-agent therapies, creating more effective and versatile treatment regimens
2Reliability
If isoxazoline parasiticide formulations are administered to achieve systemic bioavailability, then therapeutic effectiveness is improved, but the duration of protection needs to be extended
Solution Approach 1:
The patent implements periodic dosing regimens where isoxazoline formulations are administered at specific intervals (e.g., monthly or quarterly). This periodic administration maintains therapeutic blood levels while providing extended protection durations, addressing the need to balance effectiveness with prolonged action
Solution Approach 2:
The patent achieves continuous protective action through sustained-release formulations and optimized dosing schedules that maintain therapeutic drug levels in the bloodstream. This continuity ensures persistent efficacy against vector-borne pathogens while extending the duration of protection between doses
3Reliability
If multiple dosing regimens are used to ensure therapeutic efficacy, then treatment reliability is improved, but the complexity of administration increases
Solution Approach 1:
The patent divides the treatment regimen into segmented dosing schedules, such as initial loading doses followed by maintenance doses, or separate administrations for different pathogens. This segmentation allows optimization of therapeutic reliability while making the complex regimen more manageable through structured, phased administration
Solution Approach 2:
The patent develops universal formulations that can treat multiple vector-borne diseases simultaneously (e.g., Lyme disease, anaplasmosis, babesiosis) with a single isoxazoline compound or combination product. This multi-functionality reduces administrative complexity by eliminating the need for separate treatments for different pathogens
Data Source
AI summary
Disclosed herein are methods of eradicating ticks that attach to a human subject, thereby preventing potential transmission of vector-borne diseases including Lyme disease, via delivery of one, two, or more systemic doses of a lotilaner anti-parasitic therapeutic agent to the subject.